AtriCure (ATRC) Tops Q3 EPS by 10c ; Offers Guidance
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $48.17 -1.05%
Financial Fact:
Research and development expenses: 8.27M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Financial Fact:
Research and development expenses: 8.27M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q3 EPS of ($0.01), $0.10 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $134.3 million versus the consensus estimate of $131.25 million.
GUIDANCE:
AtriCure sees FY2025 EPS of ($0.23)-($0.26), versus the consensus of ($0.36). AtriCure sees FY2025 revenue of $532-534 million, versus the consensus of $530.6 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lantronix (LTRX) Reports In-Line Q4 EPS; Offers Guidance
- Pandora (P) Tops Q2 EPS by 12c; offers guidance
- Okta, Inc. (OKTA) Spike Tied to Chatter of Earnings Leak, Beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
